18 results on '"Morris, Zachary"'
Search Results
2. Abstract 6117: Dose, dose rate, and linear energy transfer influence tumor immunologic and DNA damage response following alpha- and beta-emitting radionuclides
3. Abstract 4142: CD4 T cell-driven response to immunotherapy against mouse melanoma tumors
4. Abstract 6407: Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors
5. Abstract PR006: Impact of heterogeneity for mismatch repair activity on colon tumor development and therapeutic response
6. Abstract 1306: Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models
7. Abstract 1385: The influence of MHC class I and II on T cell responses in mouse melanoma
8. Abstract 1377: Endogenous antibodies recognize multiple proteins on B78 melanoma in mice cured via immunotherapy
9. Abstract 1304: Brachytherapy dose heterogeneity primes response to immune checkpoint blockade to generate anti-tumor immunity
10. Abstract 5121: Microfluidic characterization of circulating tumor cells from mouse models and patients with head and neck cancer
11. Abstract 2255: Enhancing immunogenicity in immunologically cold ER+ breast cancer using estrogen receptor blockade and radiation therapy
12. Abstract 4055: Immune checkpoint DNA vaccines enhance anti-tumor immunity in murine melanoma model
13. Abstract 2256: Low dose brain radiotherapy enhances the efficacy of an extracranial in situ vaccine regimen against melanoma brain metastases in a pre-clinical murine model
14. Abstract 903: In vivo efficacy of bempegaldesleukin, immune checkpoint inhibition, and targeted radionuclide therapy in immunocompetent murine model of head and neck cancer
15. Abstract 902: Augmentation of anti-melanoma response by combining radiation-based in situ vaccination with GIFT4 B cell therapy
16. Abstract 1881: Immune mediated interaction between radiation and cetuximab in a syngeneic murine model of head and neck squamous cell carcinoma
17. Abstract 4440: Bempegaldesleukin (NKTR-214), a CD122 preferential IL-2 pathway agonist, augments the in situ vaccine response to radiation of an extracranial tumor in a murine melanoma model, conferring response at non-radiated tumor sites in the brain
18. In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.